...
首页> 外文期刊>Rapid Communications in Mass Spectrometry: RCM >Separation of a BMS drug candidate and acyl glucuronide from seven glucuronide positional isomers in rat plasma via high-performance liquid chromatography with tandem mass spectrometric detection
【24h】

Separation of a BMS drug candidate and acyl glucuronide from seven glucuronide positional isomers in rat plasma via high-performance liquid chromatography with tandem mass spectrometric detection

机译:通过高效液相色谱-串联质谱检测从大鼠血浆中的七个葡萄糖醛酸苷位置异构体分离BMS候选药物和酰基葡萄糖醛酸苷

获取原文
获取原文并翻译 | 示例
           

摘要

A high-performance liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been developed and validated for the determination of a BMS drug candidate and its acyl glucuronide (1-O-beta glucuronide) in rat plasma. A 50-mu L aliquot of each plasma sample was fortified with acetonitrile containing the internal standard to precipitate proteins and extract the analytes of interest. After mixing and centrifugation, the supernatant from each sample was transferred to a 96-well plate and injected into an LC/MS/MS system. Chromatographic separation was achieved isocratically on a Phenomenex Luna C-18,3 mm X 150 mm, 3 mu m column. The mobile phase contained 0.075% formic acid in 70:30 (v/v) acetonitrile/water. Under the optimized chromatographic conditions, the BMS drug candidate and its acyl glucuronide were separated from its seven glucuronide positional isomers within 10 min. Resolution of the parent from all glucuronides and acyl glucuronide from its positional isomers was critical to avoid their interference with quantitation of parent or acyl glucuronide. Detection was by positive ion electrospray MS/MS on a Sciex API 4000. The standard curve, which ranged from 5 to 5000 ng/mL, was fitted to a 1/x(2) weighted quadratic regression model for both the BMS drug candidate and its acyl glucuronide. Whole blood and plasma stability experiments were conducted to establish the sample collection, storage, and processing conditions. The validation results demonstrated that this method was rugged and repeatable. The same methodology has also been used in mouse and human plasma for the determination of the BMS drug candidate and its acyl glucuronide. Copyright (c) 2006 John Wiley & Sons, Ltd.
机译:已开发出一种高效液相色谱/串联质谱(LC / MS / MS)方法,并已用于确定大鼠血浆中BMS候选药物及其酰基葡糖醛酸苷(1-O-β葡糖醛酸苷)的有效性。每个血浆样品的50μL等分试样用含有内标的乙腈强化,以沉淀蛋白质并提取目标分析物。混合并离心后,将每个样品的上清液转移至96孔板中,并注入LC / MS / MS系统中。在Phenomenex Luna C-18,3 mm X 150 mm,3μm色谱柱上等度分离色谱。流动相在70:30(v / v)乙腈/水中含有0.075%的甲酸。在优化的色谱条件下,BMS候选药物及其酰基葡糖醛酸苷在10分钟内从其七个葡糖醛酸苷位置异构体中分离出来。母体中所有葡糖醛酸苷和酰基葡糖醛酸苷的位置异构体的拆分对于避免干扰母体或酰基葡糖醛酸苷的定量分析至关重要。通过正离子电喷雾MS / MS在Sciex API 4000上进行检测。标准曲线的范围为5至5000 ng / mL,适用于BMS候选药物和药物的1 / x(2)加权二次回归模型。它的酰基葡萄糖醛酸。进行全血和血浆稳定性实验以建立样品收集,储存和处理条件。验证结果表明该方法坚固耐用且可重复。在小鼠和人血浆中也使用了相同的方法来确定BMS候选药物及其酰基葡萄糖醛酸苷。版权所有(c)2006 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号